Safety and Efficacy of multiple doses of the PAINLESS Nerve Growth Factor CHF6467 in paediatric subjects with Optic Pathway Glioma (OPG). A randomized clinical trial (RCT)

Status

Recruiting

Phases

Phase 1Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-515753-16-00

Acronym

CHF6467-OPG

Enrollment

Registered

2024-11-05

Start date

2023-05-18

Completion date

Unknown

Last updated

2025-02-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Optic Pathway Glioma (OPG)

Brief summary

The largest radius of the field of viewmeasured in degrees visual angle by kinetic perimetry according to Goldmann with the aim V/4e

Interventions

DRUGThe Placebo composition is the same of the IMP except the active ingredient

Eligibility

Sex/Gender

All

Age

0 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
The largest radius of the field of viewmeasured in degrees visual angle by kinetic perimetry according to Goldmann with the aim V/4e	—

Countries

Italy

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026